Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Zhiling Zhang
Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
48
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Safety and Efficacy of Second-Line TKI Plus Anti-PD1 Following Targeted Therapy in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
Number of pages: 20
Posted: 17 May 2022
Jun Wang
,
Ruiqi Liu
,
Wensu Wei
,
Yang Liu
, Zhiling Zhang,
Shengjie Guo
,
Hui Han
,
Fangjian Zhou
,
Liru He
and
Pei Dong
Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China and Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China
Downloads
48
(1,097,529)
View PDF
Download
Abstract:
Immunotherapy, tyrosine kinase inhibitor, safety, efficacy, non clear cell renal cell carcinoma
Feedback
